ELTP - Elite Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0870
+0.0020 (+2.35%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.0850
Open0.0000
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume635,080
Market Cap71.383M
Beta (3Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-0.013
Earnings DateFeb 7, 2019 - Feb 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2019 Ended December 31, 2018 and Provides Conference Call Information

    Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the third quarter of fiscal year 2019 ended December 31, 2018 (“Third Quarter”). Consolidated revenues for the Third Quarter were $2.7 million, an increase of approximately 6% as compared to revenues for the comparable quarter of the prior fiscal year. Elite continues to invest in product development as $2.5 million was devoted to research and development expenses.  During the Third Quarter, in addition to the launch of Methadone, Elite received FDA approval for generic Adderall®, and generic Norco®, and filed an ANDA for an antibiotic which was co-developed with SunGen.

  • GlobeNewswire12 days ago

    Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2019 Financial Results on February 12, 2019

    Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that the third quarter financial results of the 2019 fiscal year will be released on Monday, February 11, 2019. Elite’s pipeline products include abuse-deterrent opioids which utilize the Company’s patented proprietary technology and a once-daily opioid.  These products include sustained release oral formulations of opioids for the treatment of chronic pain.

  • GlobeNewswire2 months ago

    Elite Pharmaceuticals and SunGen Pharma File ANDA for an Antibiotic

    Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for a generic version of an antibiotic product. This is the third ANDA that Elite co-developed and filed with SunGen Pharma, LLC (“SunGen”).  According to QVIA (formerly QuintilesIMS Health) data the branded product for this antibiotic and its equivalents had total annual U.S. sales of approximately $94 million for the twelve months ending September 30, 2018.

  • ACCESSWIRE6 months ago

    Elite Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Elite Pharmaceuticals, Inc. (OTCQB: ELTP ) will be discussing their earnings results in their Q1 Earnings Call to be held on August 10, 2018 at 11:00 AM Eastern ...

  • ACCESSWIRE11 months ago

    New Research: Key Drivers of Growth for U.S. Stem Cell Inc. and Elite Pharmaceuticals - Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of U.S. Stem Cell Inc. ( OTCQB: USRM ) and Elite Pharmaceuticals Inc. ...